Nanjing Medlander Medical Technology Co. Ltd. A (688273) — Net Asset Momentum
Nanjing Medlander Medical Technology Co. Ltd. A (688273) recorded a net asset momentum of -2.1% as of December 2024, with net assets of CN¥1.35 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See Nanjing Medlander Medical Technology Co. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Nanjing Medlander Medical Technology Co. Ltd. A Net Asset Momentum (2020–2024)
This chart tracks Nanjing Medlander Medical Technology Co. Ltd. A's year-over-year net asset growth across 5 annual reporting periods from 2020 to 2024. The most recent momentum reading is -2.1%, with net assets of CN¥1.35 Billion CNY as of December 2024. Read Nanjing Medlander Medical Technology Co. (688273) financial obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)
The table below shows the complete annual net asset history for Nanjing Medlander Medical Technology Co. Ltd. A from 2020 to 2024, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see market cap of Nanjing Medlander Medical Technology Co..
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥1.35 Billion | CN¥1.55 Billion | CN¥199.66 Million | ▼ -2.1% |
| 2023 | CN¥1.38 Billion | CN¥1.53 Billion | CN¥158.60 Million | ▲ +0.4% |
| 2022 | CN¥1.37 Billion | CN¥1.51 Billion | CN¥141.96 Million | ▲ +267.5% |
| 2021 | CN¥372.74 Million | CN¥488.74 Million | CN¥116.01 Million | ▲ +50.6% |
| 2020 | CN¥247.47 Million | CN¥336.15 Million | CN¥88.69 Million | — |